Literature DB >> 9322767

Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2.

S H Kim1, B Cohen, D Novick, M Rubinstein.   

Abstract

The human type I interferon (IFN) receptor consists of two essential subunits, huIFNaR1 and huIFNaR2; however, so far only IFNaR1 has been identified in other species. Furthermore, it has been suggested that in some species the type I IFN receptor may consist of a single subunit, since expression of murine IFNaR1 in human cells rendered them responsive to several type I murine IFNs. To resolve this issue, we screened a mouse cDNA library with a probe derived from huIFNaR2 cDNA. A cDNA clone, coding for a transmembrane protein which has 49% identity with huIFNaR2 was isolated. This level of identity suggests that this cDNA codes for a muIFNaR2. In addition, several cDNA clones, coding for two distinct soluble variants of muIFNaR2 were identified. To test whether muIFNaR2 is a functional component of the receptor, we co-expressed it with muIFNaR1 in human cells and with an IFN-responsive luciferase reporter vector. Treatment of these cells with muIFN-beta induced high levels of luciferase, whereas no induction was obtained in cells expressing only one of the two subunits. We therefore conclude that the murine type I IFN receptor consists of two different subunits--a configuration shared by humans, and probably all other mammals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322767     DOI: 10.1016/s0378-1119(97)00240-0

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

Review 1.  Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS.

Authors:  Koushik Chatterjee
Journal:  J Genet       Date:  2010-04       Impact factor: 1.166

Review 2.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

3.  The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice.

Authors:  G E Price; A Gaszewska-Mastarlarz; D Moskophidis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Multiple regions within the promoter of the murine Ifnar-2 gene confer basal and inducible expression.

Authors:  Matthew P Hardy; Paul J Hertzog; Catherine M Owczarek
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

5.  Antiviral activities of the soluble extracellular domains of type I interferon receptors.

Authors:  C S Han; Y Chen; T Ezashi; R M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

6.  Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.

Authors:  Kristan D Guenterberg; Valerie P Grignol; Ene T Raig; Jason M Zimmerer; Anthony N Chan; Farriss M Blaskovits; Gregory S Young; Gerard J Nuovo; Bethany L Mundy; Gregory B Lesinski; William E Carson
Journal:  Mol Cancer Ther       Date:  2010-01-26       Impact factor: 6.261

7.  Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease.

Authors:  Donna M Wilcock
Journal:  Curr Gerontol Geriatr Res       Date:  2012-02-21

8.  Age-Dependent Effects of Type I and Type III IFNs in the Pathogenesis of Bordetella pertussis Infection and Disease.

Authors:  Jeremy Ardanuy; Karen Scanlon; Ciaran Skerry; Serge Y Fuchs; Nicholas H Carbonetti
Journal:  J Immunol       Date:  2020-03-09       Impact factor: 5.422

9.  Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.

Authors:  Milton W Taylor; Takuma Tsukahara; Jeanette N McClintick; Howard J Edenberg; Paul Kwo
Journal:  J Transl Med       Date:  2008-11-05       Impact factor: 5.531

Review 10.  Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis.

Authors:  Donna M Wilcock; W Sue T Griffin
Journal:  J Neuroinflammation       Date:  2013-07-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.